Fennec Pharmaceuticals is trading at $11.80, up +7.86% in after-hours trading, ahead of second-quarter 2026 results.
- The move followed a 5.49% regular-session decline to $10.94 on August 10, 2026.
- Results are scheduled before the U.S. market open on August 11, with management’s call at 8:30 a.m. Eastern Time.
- No additional company-specific announcement or released earnings result was identified; positioning ahead of the report appears to be the catalyst.